Clinical trials: Oral Phase
Candidemia, Mycoses
Study of Rezafungin Compared to Caspofungin in Subjects With Candidemia and/or Invasive Candidiasis
The purpose of this pivotal study is to determine if intravenous Rezafungin is efficacious and safe in the treatment of candidemia and/or invasive candidiasis when compared to caspofungin (followed by optional oral fluconazole).
- Conditions
- Candidemia, Mycoses, Fungal Infection, Invasive Candidiases
- Trial name
- ReSTORE (NCT03667690)
- Testing
- Rezafungin for Injection, Caspofungin, Fluconazole
- Where
- 132 sites in United States, Argentina and 16 more
- Volunteers
- 199 people
- Sponsor
- Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Estrogen Receptor-positive Breast Cancer, HER2-negative Breast Cancer
Mucoadhesive Oral Wound Rinse in Preventing and Treating Stomatitis in Patients With ER- or PR-Positive Metastatic or Locally Recurrent Breast Cancer That Cannot be Removed by Surgery Receiving Everolimus
This randomized phase II trial studies how well mucoadhesive oral wound rinse works in preventing and treating stomatitis in patients with estrogen receptor (ER)- or progesterone receptor (PR)-positive metastatic or locally…
- Conditions
- Estrogen Receptor-positive Breast Cancer, HER2-negative Breast Cancer, Oral Complications, Progesterone Receptor-positive Breast Cancer
- Trial name
- NCT02015559
- Testing
- mucoadhesive oral wound rinse, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 61 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Peanut Allergy
Oral Immunotherapy for Peanut Allergic Patients
Multicenter, double-blind, randomized, placebo-controlled phase I/II study to determine the safety, tolerability, potential efficacy and dose finding of INP20, an oral immunotherapy in peanut-allergic patients.
- Trial name
- NCT04163562
- Testing
- INP20
- Where
- 2 sites in Spain
- Volunteers
- 50 people
- Sponsor
- InnoUp Farma S.L.
Diabetic Nephropathy
6-Month Safety And Efficacy Study Of TTP488 In Patients With Type 2 Diabetes And Persistent Albuminuria
Current research indicates that TTP488 may be a viable agent for the treatment of diabetic nephropathy. The purpose of this study is to determine the safety and efficacy of a six-month regimen of daily orally-administered TTP488…
- Trial name
- NCT00287183
- Testing
- PF-04494700 (TTP488)
- Where
- 19 sites in Canada
- Volunteers
- 110 people
- Sponsor
- Pfizer
Periodontal Disease, Periodontal Disease Stage 2
Probiotics And Ozonated Olive Oil To Maintain Oral Eubiosis In Stage I And II Periodontitis Patients
The goal of this clinical trial is to investigate the clinical benefits of the combined use of ozonized olive oil products (mouthwash and toothpaste) and probiotics on the health status of patients with Stage I and II…
- Trial name
- NCT06955546
- Testing
- Toothpaste Product, Mouthwash Product, Probiotic
- Where
- Italy
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- Massimo Corsalini
Anemia of Chronic Kidney Disease
A Study to Investigate the Effect of Roxadustat Versus Recombinant Human Erythropoietin (rHuEPO) on Oral Iron Absorption in Chinese Patients With Anemia of Chronic Kidney Disease (CKD)
This is a Phase IV, randomized, active-controlled, open-label, parallel design, multicenter prospective study to evaluate the effect of roxadustat versus rHuEPO treatment on the gastrointestinal (GI) iron absorption in patients…
- Trial name
- NCT04655027
- Testing
- Roxadustat, rHuEPO
- Where
- 8 sites in China
- Volunteers
- 25 people
- Sponsor
- AstraZeneca
Sjogren's Syndrome
Study to Assess Safety and Efficacy of Filgotinib, Lanraplenib and Tirabrutinib in Adults With Active Sjogren's Syndrome
The primary objective of this study is to assess the efficacy of filgotinib, lanraplenib, and tirabrutinib in adults with active Sjogren's Syndrome (SjS).
- Trial name
- NCT03100942
- Testing
- Lanraplenib, Filgotinib, Tirabrutinib
- Where
- 53 sites in United States, Poland and 2 more
- Volunteers
- 152 people
- Sponsor
- Gilead Sciences
Breast Cancer
Safety and Efficacy of BKM120 and Lapatinib in HER2+/PI3K-activated, Trastuzumab-resistant Advanced Breast Cancer
This study is based upon the following points: 1. Resistance to trastuzumab, either primary or secondary, is a clinically relevant issue. 2.
- Trial name
- PIKHER2 (NCT01589861)
- Testing
- BKM120 + lapatinib
- Where
- France
- Volunteers
- 24 people
- Sponsor
- Institut Paoli-Calmettes
Healthy
A Study Comparing the Amounts of 2 Different Forms of Tafamidis (PF06291826), Both With and Without Food, In the Blood
2 different formulations of tafamidis will be compared under both fed and fasted conditions. Subjects will be fasted overnight or fed.
- Trial name
- NCT03280173
- Testing
- tafamidis
- Where
- Belgium
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Pfizer
Migraine
Efficacy and Tolerability of Rimegepant for the Prevention of Migraine in Adults With History of Inadequate Response to Oral Preventive Medications
This study is being conducted to evaluate the efficacy and tolerability of rimegepant for migraine prophylaxis in adults with a history of inadequate response to oral preventive medications
- Trial name
- NCT05518123
- Testing
- Rimegepant
- Where
- 111 sites in United States, Australia and 12 more
- Volunteers
- 962 people
- Sponsor
- Pfizer
Bioavailability and Pharmacokinetics
Relative Bioavailability of HTL0018318 Oral Aqueous Solution Versus Capsules
HTL0018318 is a selective muscarinc M1 agonist. This study is a phase I, open label, randomised, crossover, single dose, trial in healthy volunteers to compare the relative bioavailability of HTL0018318 when given by oral aqueous…
- Trial name
- NCT02958696
- Testing
- HTL0018318
- Where
- United Kingdom
- Volunteers
- 37 people, healthy volunteers welcome
- Sponsor
- Nxera Pharma UK Limited
Neoplasms, Head and Neck
Lapatinib Versus Placebo Given Concurrently With Cisplatin And Radiotherapy In Patients With Unresected Head And Neck Cancer
This is a phase II study comparing the effects of lapatinib versus placebo when administered concurrently with cisplatin and radiotherapy followed by 1 year monotherapy with lapatinib or placebo.
- Trial name
- NCT00387127
- Testing
- Lapatinib oral tablets, radiotherapy, cisplatin chemotherapy
- Where
- 30 sites in United States, Canada and 7 more
- Volunteers
- 67 people
- Sponsor
- GlaxoSmithKline
Mouth Neoplasms, Oral Cancers
Sentinel Node Biopsy Versus Limited Elective Neck Dissection in Early Cancers of Oral Cavity NoDe Negative
The goal of this clinical trial is to compare the survival outcomes, morbidity and cost-effectiveness of sentinel node biopsy versus limited elective neck dissection in node-negative early oral cancers.
- Conditions
- Mouth Neoplasms, Oral Cancers, Oral Squamous Cell Carcinoma (OSCC), Oral Squamous Cell Carcinomas
- Trial name
- SECOND N0 (NCT05774483)
- Testing
- Sentinel Node Biopsy, Limited Elective Neck Dissection
- Where
- 3 sites in India
- Volunteers
- 508 people
- Sponsor
- Tata Memorial Hospital
Pompe Disease (Late-onset)
A Study Comparing ATB200/AT2221 With Alglucosidase Alfa/Placebo in Adult Subjects With Late-onset Pompe Disease
This is a phase 3 double-blind randomized study to study the efficacy and safety of intravenous ATB200 Co-administered with oral AT2221 in adult subjects with Late Onset Pompe Disease compared with Alglucosidase Alfa/placebo.
- Trial name
- PROPEL (NCT03729362)
- Testing
- Cipaglucosidase Alfa, Miglustat, Alglucosidase Alfa
- Where
- 73 sites in United States, Argentina and 22 more
- Volunteers
- 125 people
- Sponsor
- Amicus Therapeutics
Squamous Cell Carcinoma of the Head and Neck
A Phase 2 Clinical Trial of the Safety and Effects of IRX-2 in Treating Patients With Operable Head and Neck Cancer
This was a Phase 2a trial to investigate the safety and biological activity of the RIX-2 Regimen in patients with untreated, resectable squamous cell cancer of the head and neck (HNSCC).
- Trial name
- NCT00210470
- Testing
- IRX-2, Cyclophosphamide, Indomethacin
- Volunteers
- 27 people
- Sponsor
- Brooklyn ImmunoTherapeutics, LLC
Hearing Loss
Evaluation of the Presence of SENS-401 in the Perilymph
The aim of this study is to detect the presence of SENS-401 in the perilymph of participants undergoing cochlear implant surgery after 7 days of oral administration of SENS-401.
- Trial name
- NCT05258773
- Testing
- SENS-401 (R-Azasetron Besylate)
- Where
- 7 sites in Australia, France
- Volunteers
- 28 people
- Sponsor
- Sensorion
Leukemia, Relapsed Leukemia
Roginolisib (IOA-244) With Venetoclax and Rituximab for Refractory/Relapsed Chronic Lymphocytic Leukemia (CLL)
This research study will test the safety and anticancer activity of the combination of three drugs (Roginolisib, Venetoclax, and Rituximab) for participants with relapsed or refractory Chronic Lymphocytic Leukemia (CLL).
- Conditions
- Leukemia, Relapsed Leukemia, Chronic Lymphocytic Leukemia, Relapsed Cancer
- Trial name
- NCT06644183
- Testing
- Roginolisib, Venetoclax, Rituximab
- Where
- United States
- Volunteers
- 64 people
- Sponsor
- Jennifer R. Brown, MD, PhD
Healthy
Single and Multiple Ascending Doses of AZD1981 in Japan
The purpose of this study is to study safety, tolerability and pharmacokinetics of AZD1981 in healthy Japanese subjects
- Trial name
- JSAD/JMAD (NCT00698282)
- Testing
- AZD1981
- Where
- United Kingdom
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Olmsted Syndrome
Study of KM-023 in Healthy Volunteers and Patients With Olmsted Syndrome.
The trial is conducted in order to assess the safety of KM-023 and to observe what effects, both beneficial and adverse, it has on the body, and the way the body absorbs and eliminates KM-023, first in healthy participants, then…
- Trial name
- NCT07090889
- Testing
- KM-023
- Where
- 4 sites in United States, France and 1 more
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Orvida Pharma (formerly Kamari Pharma)
Acute Myeloid Leukemia
A Phase I-II Study Investigating the All-Oral Combination of the Menin Inhibitor SNDX-5613 With Decitabine/Cedazuridine (ASTX727) and Venetoclax in Acute Myeloid Leukemia (SAVE)
Part 1b of this clinical research study is to find the highest tolerable dose of SNDX-5613 that can be given in combination with ASTX727 (a combination of the drugs decitabine/cedazuridine) and venetoclax for patients with acute…
- Trial name
- NCT05360160
- Testing
- SNDX-5613, Venetoclax, ASTX727
- Where
- United States
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- M.D. Anderson Cancer Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.